https://scholars.lib.ntu.edu.tw/handle/123456789/627198
標題: | Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib | 作者: | Kudo, Masatoshi Finn, Richard S Edeline, Julien Cattan, Stéphane Ogasawara, Sadahisa Palmer, Daniel H Verslype, Chris Zagonel, Vittorina Fartoux, Laetitia Vogel, Arndt Sarker, Debashis Verset, Gontran Chan, Stephen L Knox, Jennifer Daniele, Bruno Yau, Thomas Gurary, Ellen B Siegel, Abby B Wang, Anran ANN-LII CHENG Zhu, Andrew X |
關鍵字: | Advanced hepatocellular carcinoma; Anti-PD-1; Long-term treatment; Pembrolizumab | 公開日期: | 五月-2022 | 出版社: | ELSEVIER SCI LTD | 卷: | 167 | 起(迄)頁: | 1 | 來源出版物: | European journal of cancer (Oxford, England : 1990) | 摘要: | Pembrolizumab, a PD-1 inhibitor, demonstrated anti-tumour activity and tolerability in patients treated with sorafenib and with advanced hepatocellular carcinoma in KEYNOTE-224. Longer-term efficacy and safety after ∼2.5 years of additional follow-up are reported. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627198 | ISSN: | 0959-8049 | DOI: | 10.1016/j.ejca.2022.02.009 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。